Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

848
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
848
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

565
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
565
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

847
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
847
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

773
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
773
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

698
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
698
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

385
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
385

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microbial Food Safety Assessment of Organic Food and Feed: Notifications in the EU RASFF during 2020-2022. A Systematic Review.

Transboundary and emerging diseases·2025
Same author

Comparison of culture-dependent and -independent bacterial detection results on nasal swabs in dogs with nasal discharge.

The Journal of small animal practice·2024
Same author

Individual differences in behaviour and gut bacteria are associated in collared peccary (Mammalia, Tayassuidae).

Journal of applied microbiology·2021
Same author

Gut microbiota, body weight and histopathological examinations in experimental infection by methicillin-resistant <i>Staphylococcus aureus</i>: antibiotic versus bacteriocin.

Beneficial microbes·2021
Same author

Monitoring of Hygiene in Institutional Kitchens in Belgium.

Journal of food protection·2020
Same author

Corrigendum to "<i>Clostridium difficile</i> beyond stools: dog nasal discharge as a possible new vector of bacterial transmission" [Heliyon 5 (5) (May 2019) e01629].

Heliyon·2019

Related Experiment Video

Updated: Dec 27, 2025

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.1K

MICROBIOTA INSIGHTS IN CLOSTRIDIUM DIFFICILE INFECTION AND INFLAMMATORY BOWEL DISEASE.

C Rodríguez1,2, E Romero1, L Garrido-Sanchez1,3

  • 1Instituto de Investigación Biomédica de Málaga-IBIMA , Málaga, Spain.

Gut Microbes
|March 5, 2020
PubMed
Summary

Inflammatory bowel disease (IBD) involves gut microbiota dysbiosis, increasing susceptibility to Clostridium difficile infection (CDI). This review explores IBD and CDI-associated gut microbiome changes and their therapeutic implications.

Keywords:
C. difficileinflammatory bowel diseaseinteractionsmicrobial communitiesmicrobial metabolites

More Related Videos

Investigation of Microbial Cooperation via Imaging Mass Spectrometry Analysis of Bacterial Colonies Grown on Agar and in Tissue During Infection
09:49

Investigation of Microbial Cooperation via Imaging Mass Spectrometry Analysis of Bacterial Colonies Grown on Agar and in Tissue During Infection

Published on: November 18, 2022

2.6K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.3K

Related Experiment Videos

Last Updated: Dec 27, 2025

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.1K
Investigation of Microbial Cooperation via Imaging Mass Spectrometry Analysis of Bacterial Colonies Grown on Agar and in Tissue During Infection
09:49

Investigation of Microbial Cooperation via Imaging Mass Spectrometry Analysis of Bacterial Colonies Grown on Agar and in Tissue During Infection

Published on: November 18, 2022

2.6K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.3K

Area of Science:

  • Gastroenterology
  • Microbiology
  • Immunology

Background:

  • Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is linked to genetic, immune, and gut microbiota factors.
  • Gut dysbiosis, an imbalance in the gut microbial community, plays a crucial role in IBD pathogenesis and exacerbation.
  • Opportunistic pathogens like Clostridium difficile can infect the compromised gut environment in IBD patients, triggering flares.

Purpose of the Study:

  • To review and analyze gut microbiota alterations in Inflammatory Bowel Disease (IBD) patients with and without Clostridium difficile infection (CDI).
  • To compare the dysbiosis patterns observed in IBD and CDI, highlighting similarities and differences.
  • To discuss metabolic pathways influencing microbial taxa relevant to IBD and CDI.

Main Methods:

  • Literature review of studies investigating gut microbiota in IBD and CDI.
  • Comparative analysis of microbial community structures and functions.
  • Exploration of metabolic pathways implicated in disease development.

Main Results:

  • IBD patients exhibit significant gut dysbiosis, characterized by altered microbial composition and function.
  • Concomitant CDI in IBD patients shows distinct but overlapping dysbiosis patterns compared to IBD alone.
  • Loss of bacterial cooperation and shifts in specific microbial taxa are evident in IBD with CDI.

Conclusions:

  • Gut microbiota dysbiosis is a central feature of both IBD and CDI, with shared and distinct characteristics.
  • Understanding these microbial interrelations is crucial for developing novel therapeutic strategies for IBD and CDI.
  • Targeting microbial pathways may offer new avenues for managing IBD flares triggered by CDI.